Abstract:Abstract Background Long non-coding RNAs are important regulators of gene expression and diverse biological processes. Their aberrant expression contributes to a verity of diseases including cancer development and progression, providing them with great potential to be diagnostic and prognostic biomarkers and therapeutic targets. Therefore, they can have a key role in personalized cancer medicine. This review aims at introducing possible strategies to target long ncRNAs therapeutically in cancer. Also, chemical modification of nucleic acid-based therapeutics to improve their pharmacological properties is explained. Then, approaches for the systematic delivery of reagents into the tumor cells or organs are briefly discussed, followed by describing obstacles to the expansion of the therapeutics. Main text Long ncRNAs function as oncogenes or tumor suppressors, whose activity can modulate all hallmarks of cancer. They are expressed in a very restricted spatial and temporal pattern and can be easily detected in the cells or biological fluids of patients. These properties make them excellent targets for the development of anticancer drugs. Targeting methods aim to attenuate oncogenic lncRNAs or interfere with lncRNA functions to prevent carcinogenesis. Numerous strategies including suppression of oncogenic long ncRNAs, alternation of their epigenetic effects, interfering with their function, restoration of downregulated or lost long ncRNAs, and recruitment of long ncRNAs regulatory elements and expression patterns are recommended for targeting long ncRNAs therapeutically in cancer. These approaches have shown inhibitory effects on malignancy. In this regard, proliferation, migration, and invasion of tumor cells have been inhibited and apoptosis has been induced in different cancer cells in vitro and in vivo. Downregulation of oncogenic long ncRNAs and upregulation of some growth factors (e.g., neurotrophic factor) have been achieved. Conclusions Targeting long non-coding RNAs therapeutically in cancer and efficient and safe delivery of the reagents have been rarely addressed. Only one clinical trial involving lncRNAs has been reported. Among different technologies, RNAi is the most commonly used and effective tool to target lncRNAs. However, other technologies need to be examined and further research is essential to put lncRNAs into clinical practice.

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Therapeutic advances of targeting receptor tyrosine kinases in cancer

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

Strategies to target long non-coding RNAs in cancer treatment: progress and challenges

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

Unveiling the Future of Cancer Treatment: A Cutting‐Edge Review on the Role of Nanotherapeutics in Targeting Long Non‐Coding RNAs

Non-coding RNAs as therapeutic targets in cancer and its clinical application

The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer

Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization

Non-Coding RNAs: Key Regulators of CDK and Wnt/β-catenin signaling in Cancer

The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer

Potential therapies for non-coding RNAs in breast cancer

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review